Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow LYEL
Lyell Immunopharma, Inc. (LYEL) Altman Z-score
Lyell Immunopharma, Inc.'s Altman Z-score for fiscal 2025 is −5.10, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −5.10 | (0.58) |
| FY2024 | −4.52 | (5.47) |
| FY2023 | 0.95 | (3.06) |
| FY2022 | 4.00 | 1.54 |
| FY2021 | 2.47 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.62 | — | 0.75 | |
| Retained earnings / total assets | (4.76) | — | −6.67 | |
| EBIT / total assets | (0.79) | — | −2.61 | |
| Market value of equity / total liabilities | 5.73 | — | 3.44 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −5.10 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −13.93 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NAGE Niagen Bioscience, Inc. compare | 10.5× |
| IVVD Invivyd, Inc. compare | 2.9× |
| CGEN Compugen Ltd. compare | −0.4× |
| PRQR ProQR Therapeutics N.V. compare | −4.4× |
| RNAC Cartesian Therapeutics, Inc. compare | −4.7× |
| LYEL Lyell Immunopharma, Inc. | −5.1× |
| ADCT ADC Therapeutics SA compare | −6.7× |
| STRO Sutro Biopharma, Inc. compare | −9.6× |
| LRMR Larimar Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets